Site search2025
- 2025.7.3PRU.S. FDA Orphan Drug Designation Granted to BP2202 for the Treatment of Multiple Myeloma（87KB）
- 2025.6.19PRBrightPath Presented Data on Bispecific Antibody BP1212 for Cancer Therapy at IRCI 2025（95KB）
- 2025.6.13PRBrightpath to Present Data on Bispecific Antibody BP1212 for Cancer Immunothearpy at IRCI 2025（79KB）
- 2025.5.13PRBrightPath Presented Manufacturing Process Development Updates for iPS Cell-derived BCMA CAR-iNKT Cells (BP2202) at ASGCT 2025（130KB）
- 2025.5.9IRFinancial Results for the Fiscal Year ended March 31, 2025 [Japanese GAAP] (non-consolidated)（462KB）
- 2025.5.8PRBrightPath to Present the Data of Manufacturing Process of iPS Cell-derived BCMA CAR-iNKT Cells (BP2202) at ASGCT 2025（151KB）
- 2025.4.29PRBrightPath Presented the Preclinical Data of iPSC-derived HER2 CAR-iNKT cells at AACR 2025（83KB）
- 2025.3.27PRBrightPath to Present the Preclinical Data of iPSC-derived HER2 CAR-iNKT cells at AACR 2025（106KB）
- 2025.2.14IRFinancial Results for the Nine Months ended December 31, 2024 [Japanese GAAP] (non-consolidated)（311KB）
- 2025.7.3PRU.S. FDA Orphan Drug Designation Granted to BP2202 for the Treatment of Multiple Myeloma（87KB）
- 2025.6.19PRBrightPath Presented Data on Bispecific Antibody BP1212 for Cancer Therapy at IRCI 2025（95KB）
- 2025.6.13PRBrightpath to Present Data on Bispecific Antibody BP1212 for Cancer Immunothearpy at IRCI 2025（79KB）
- 2025.5.13PRBrightPath Presented Manufacturing Process Development Updates for iPS Cell-derived BCMA CAR-iNKT Cells (BP2202) at ASGCT 2025（130KB）
- 2025.5.8PRBrightPath to Present the Data of Manufacturing Process of iPS Cell-derived BCMA CAR-iNKT Cells (BP2202) at ASGCT 2025（151KB）
- 2025.4.29PRBrightPath Presented the Preclinical Data of iPSC-derived HER2 CAR-iNKT cells at AACR 2025（83KB）
- 2025.3.27PRBrightPath to Present the Preclinical Data of iPSC-derived HER2 CAR-iNKT cells at AACR 2025（106KB）